. Author manuscript; available in PMC: 2011 Aug 30.

Published in final edited form as: Int J Pharm. 2010 Jul 1;396(1-2):111–118. doi: 10.1016/j.ijpharm.2010.06.039

Table 2.

LC-MS/MS methods of analyzing CDCA-lysine-niacin and CDCA-lysine-ketoprofen and the parent drugs niacin and ketoprofen.

Compound	Exact Mass ^a	Q1 Mass (m/z) ^b	Q3 Mass (m/z)	Retention Time (min)	Gradient Timetable (B%)^c
CDCA-lysine-niaicn	625.41	626.40	189.12	1.26	0–0.2 (45%), 0.2–3.0 (45–95%), 3.0–4.0 (95%), 4.0–4.2 (95-45%), and 4.2–7.0 min (45%)
Niacin	123.03	124.06	80.15	1.02	0–3.1 (5%), 3.1–3.2 (5–90%), 3.2–4.2 (90%), 4.2–4.5 (90%-5%), and 4.5–8.0 min (5%)
CDCA-lysine-ketoprofen	756.47	757.50	485.30	4.77	0–0.2 (40%), 0.2–3.0 (40–95%), 3.0–4.0 (95%), 4.0–4.2 (95-40%), and 4.2–7.0 min (40%)
Ketoprofen	254.09	255.10	198.36	2.36	0–0.2 (40%), 0.2–3.0 (40–95%), 3.0–4.0 (95%), 4.0–4.2 (95-40%), and 4.2–7.0 min (40%)

Calculated monoisotopic mass.

Q1 and Q3 mass are experimental mass [M+H]⁺.

The mobile phase was A, 0.1% formic acid in water; and B, 0.1% formic acid in acetonitrile. The gradient times were listed as the percent organic phase, B%.